Posts Tagged ‘psychotic symptoms’

Scandalous Off Label Use Of Antipsychotics: Another Warning For DSM-5

Monday, August 8th, 2011

Psychiatric Times

By Allen Frances, MD | August 5, 2011

I never would have entered the DSM-5 controversy were it not for two of its proposals that risk furthering the already frightening overuse of antipsychotic medication, particularly in children and teenagers. DSM-5 plans to introduce two new and untested diagnoses that would offer natural targets for poor drug prescribing–psychosis risk syndrome (AKA attenuated psychotic symptoms) and temper dysregulation (AKA disruptive mood dysregulation). There is no evidence whatever that antipsychotics would confer any benefit on the kids so labeled (and too often mislabeled), but great reason to worry that this would not stop their being used needlessly and recklessly.

The DSM-5 supporters of these two proposals believe my concern is ill founded, or at least excessive. They argue that they would not recommend antipsychotics for the new diagnoses and that there is no FDA approved indication for their use. This misses the crucial point that new DSM categories, once made official, take on an independent life. If they can possibly be misused (and clearly these can), they will be misused. And experience teaches the clear lesson that antipsychotic overuse will insinuate itself insidiously and inappropriately whenever any crack of opportunity opens up.

A recent paper by Mojtabai and Olfson1 presents a chilling testimony to the spreading creep of antipsychotic misuse. In 1996, antipsychotics were prescribed for patients with an anxiety disorder in 10% of office visits. One decade later, this had more than doubled despite there being no evidence that antipsychotics work for anxiety disorders and clear evidence that they cause dangerous side effects. Because antipsychotics have no FDA indication for anxiety disorders, all this massive overprescription was done completely off-label.

This is truly alarming, but unfortunately it is not really surprising. Antipsychotics have managed to become the top class of drugs– generating the highest revenue with sales of $15 billion per year– despite the troubling facts that much of the prescribing is off label, unsupported by scientific evidence, and likely to cause the dreadful side effect of obesity with all its consequent risks. This is an astounding reflection on the lack of caution in everyday medical practice. Used appropriately, antipsychotics are extremely valuable and necessary tools– but what could possibly justify their becoming such promiscuous best sellers?

DSM-5 cannot off-load responsibility for causing harmful unintended consequences– especially when these are so obvious that they smack you in face. It is foolhardy to risk causing a further wave in the antipsychotic deluge. I continue to despair of a process that allows such smart and well meaning people to make such really dreadful decisions.

 https://member.cmpmedica.com/index.php?referrer=http://member.cmpmedica.com/cga.php?assetID=422&referrer=http://www.psychiatrictimes.com/blog/couchincrisis/content/article/10168/1921927

« Return to news items


Share

Huffington Post: Poor Kids far more likely to be prescribed psychiatric drugs

Thursday, May 20th, 2010

Huffington Post
By Bruce E. Levine
May 20, 2010

Children covered by Medicaid are far more likely to be prescribed antipsychotic drugs than children covered by private insurance, and Medicaid-covered kids have a higher likelihood of being prescribed antipsychotics even if they have no psychotic symptoms. This is reported in the May19, 2010 Journal of American Medical Association (JAMA) article, “Studies Shed Light on Risks and Trends in Pediatric Antipsychotic Prescribing.”

Researchers at Rutgers University and Columbia University found that children and adolescents covered by Medicaid were four times as likely as those with private insurance to receive an antipsychotic in 2004. Among those aged six to 17 years who were covered by Medicaid, 4.2 percent were prescribed at least one antipsychotic drug. In contrast, among those in this same age group who had private insurance, less than 1 percent were prescribed an antipsychotic. Nearly half of these Medicaid-covered pediatric patients receiving antipsychotic drugs had nonpsychotic diagnoses of attention deficit hyperactivity disorder (ADHD) or some other disruptive behavior disorder. In contrast, of the privately insured pediatric patients receiving antipsychotics, about one fourth were diagnosed with ADHD or some other disruptive behavior disorder.

The current issue of JAMA also reports another troubling study published earlier this year in the journal Pediatrics. This study, conducted by Robert Penfold of the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute, examined the use of the antipsychotic Geodon (ziprasidone) in pediatric patients covered by Medicaid in Michigan in 2001. Of the pediatric patients who had been diagnosed with a psychiatric disorder and had received Geodon, only 53.3 percent actually had a diagnosis of psychosis. The other children who received Geodon had one or more of the following diagnoses: 24.1 percent were diagnosed with explosive personality disorder, 17.6 percent were diagnosed with depressive disorder, and 13.1 percent of these kids who were prescribed Geodon had oppositional defiant disorder (ODD). What exactly does it take to get an ODD diagnosis?

Read entire article:  http://www.huffingtonpost.com/bruce-e-levine/psychiatric-drugs-and-poo_b_583568.html

« Return to news items


Share